Use of 20% intravenous lipid emulsion for the treatment of loperamide toxicosis in a Collie homozygous for the ABCB1-1∆ mutation

J Vet Emerg Crit Care (San Antonio). 2017 May;27(3):357-361. doi: 10.1111/vec.12562. Epub 2016 Dec 19.

Abstract

Objective: To describe the successful treatment of loperamide toxicosis in a dog using intravenous lipid emulsion (ILE).

Case summary: An 8-month-old male neutered Rough Collie weighing 20.0 kg was given a total dose of 0.75 mg/kg loperamide over 3 days as treatment for diarrhea. The dog was subsequently evaluated for signs of dull mentation, anxiety, ptyalism and ataxia, thought to be a result of loperamide intoxication. The dog was treated with a 1.5 mL/kg IV bolus of 20% ILE solution followed by 0.25 mL/kg/min of the same solution for 2 hours. The dog's mentation improved rapidly following ILE infusion, and he was neurologically normal 3 hours after initiation of ILE treatment. The dog was subsequently found to be homozygous for the ATP-binding cassette (ABC) transporter gene (ABCB1-1∆) mutation. There were no adverse effects noted during or following ILE infusion.

New or unique information provided: ILE was successful in the treatment of loperamide toxicosis in a Collie with the ABCB1-1∆ mutation. ILE may be of benefit for treatment of other intoxications in dogs with ABCB1-1Δ mutations.

Keywords: P-glycoprotein; antidote; central nervous system; mutation; neurotoxicosis.

Publication types

  • Case Reports

MeSH terms

  • ATP Binding Cassette Transporter, Subfamily B, Member 1 / genetics*
  • Animals
  • Antidiarrheals / adverse effects*
  • Diagnosis, Differential
  • Diarrhea / drug therapy
  • Diarrhea / veterinary
  • Dog Diseases / diagnosis*
  • Dog Diseases / drug therapy
  • Dog Diseases / genetics
  • Dogs
  • Drug-Related Side Effects and Adverse Reactions / diagnosis
  • Drug-Related Side Effects and Adverse Reactions / drug therapy
  • Drug-Related Side Effects and Adverse Reactions / veterinary*
  • Emergencies / veterinary
  • Fat Emulsions, Intravenous / therapeutic use*
  • Loperamide / adverse effects*
  • Male
  • Mutation

Substances

  • ATP Binding Cassette Transporter, Subfamily B, Member 1
  • Antidiarrheals
  • Fat Emulsions, Intravenous
  • Loperamide